The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new antifungal drug class in 20 years.
Direct-to-consumer startup Thirty Madison targets a new customer: health plans
Direct-to-consumer startup Thirty Madison targets a new customer: health plans
The startup, which currently has four direct-to-consumer brands, recently passed a $1 billion valuation. It plans to use the funds to market its services to a new customer: health plans.
Shares0
As investors continue to pour funds into direct-to-consumer health startups, one of them, Thirty Madison, is looking to win over a new type of customer.
The startup recently raised $140 million in funding, and plans to use a portion of that to strike partnerships with employers and payers.
In an emailed statement, CEO and Co-Founder Steven Gutentag said working with employer and payor networks would allow the company to reach more patients and expand its treatment offerings. The company didn’t disclose which, and how many, partners Thirty Madison currently has.
Bettina Hein
Bettina Hein is CEO and Co-Founder of juli, an app that uses AI to help people manage their chronic conditions by surfacing behavioral triggers that encourage healthy decisions. A serial software entrepreneur, Hein has built successful technology companies in Europe and the US. She is founder and past CEO of Pixability, a Boston-based company that provides data-driven insights, precise targeting technology, and social video expertise to help marketers find and engage their audiences across YouTube, Facebook, Instagram, Twitter, and Snapchat. She also co-founded SVOX AG, a Switzerland-based embedded speech technology company that was acquired in 2011 by Nuance Communications for $125M. Hein is a Young Global Leader at the World Economic Forum, and a judge on the Swiss version of TV’s “Shark Tank.”
Auris Medical has acquired Trasir Therapeutics, a startup developing technology that expands the delivery of RNA medicines to tissues beyond the liver. Going forward, Auris will sell or spin off its programs in hearing disorders and allergies and focus exclusively on RNA therapies.
It’s time to gear our machine learning tools to this data so that people with chronic illnesses and especially, complex chronic conditions can get the same kind of recommendations that they use every day to pick their movies or music or buy goods on the Internet.